Abstract
BackgroundFor patients with advanced non-small cell lung carcinoma (NSCLC), immune check point inhibitor (ICPI) and chemotherapy (chemo)-ICPI represent 2 distinct first-line standard-of-care regimens without clear and established biomarkers to inform...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have